Snowden Capital Advisors LLC Has $515,000 Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Snowden Capital Advisors LLC grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 84.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,862 shares of the medical equipment provider’s stock after buying an additional 2,227 shares during the quarter. Snowden Capital Advisors LLC’s holdings in Zimmer Biomet were worth $515,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $25,000. Accredited Wealth Management LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $36,000. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $39,000. OFI Invest Asset Management acquired a new stake in Zimmer Biomet in the fourth quarter worth about $40,000. Finally, Dunhill Financial LLC increased its position in Zimmer Biomet by 86.6% in the fourth quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 206 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on ZBH. Wells Fargo & Company lowered their price objective on Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. Morgan Stanley lowered their price objective on Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. Canaccord Genuity Group lowered their price objective on Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating for the company in a research report on Monday, May 12th. Truist Financial set a $101.00 price objective on Zimmer Biomet in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $113.45.

Zimmer Biomet Trading Down 0.6%

NYSE:ZBH opened at $95.21 on Wednesday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.92 and a fifty-two week high of $120.13. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a market capitalization of $18.84 billion, a PE ratio of 21.40, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The business’s 50-day simple moving average is $102.99 and its 200-day simple moving average is $105.68.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The business had revenue of $1.91 billion for the quarter, compared to analysts’ expectations of $1.89 billion. During the same quarter in the previous year, the business posted $1.94 EPS. Zimmer Biomet’s revenue for the quarter was up 1.1% on a year-over-year basis. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.01%. The ex-dividend date was Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.24%.

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.39% of the stock is currently owned by company insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.